Publications by authors named "J P Sands"
What Is This Summary About?: This is a summary of a phase 2 clinical study called DeLLphi-301. The study looked at how effective and safe a medicine called tarlatamab was in participants with small cell lung cancer (SCLC). Participants previously received at least two other treatments for their SCLC.
View Article and Find Full Text PDFOur previous work established a role for actin associated myosin motor proteins MYH9 and MYH10 in the trafficking of thick ascending limb (TAL) specific cargoes, uromodulin (UMOD) and Na + K + 2Cl- cotransporter (NKCC2). Here, we have generated a TAL-specific Myh9&10 conditional knockout (Myh9&10 TAL-cKO) mouse model to determine the cell autonomous roles for MYH9&10 proteins in TAL cargo transport and to understand the consequence of TAL dysfunction in the adult kidney. Myh9&10 TAL-cKO mice develop progressive kidney disease with pathological tubular injury confirmed by histological changes, tubular injury markers, upregulation of ER stress/unfolded protein response pathway, and higher blood urea nitrogen and serum creatinine.
View Article and Find Full Text PDFCrizotinib successfully overcomes MET amplification in ROS1-rearranged NSCLC after entrectinib failure.
View Article and Find Full Text PDFArticle Synopsis
- Large-scale studies indicate that exogenous erythropoietin and erythropoiesis-stimulating agents do not protect the kidneys from damage.
- The study investigated the effects of daprodustat on chronic renal failure progression in patients with moderate to severe chronic kidney disease, finding it slowed the decline in renal function and helped some patients recover.
- Daprodustat is beneficial for both renal anemia and preserving kidney function, though its protective effects are limited in patients with very high serum creatinine levels.
Purpose: The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with pretreated advanced/metastatic non-small cell lung cancer (NSCLC).
Methods: Patients received Dato-DXd 6 mg/kg or docetaxel 75 mg/m once every 3 weeks. Dual primary end points were progression-free survival (PFS) and overall survival (OS).